Approximately 300 million individuals worldwide experience issues with social connectedness and interpersonal relations.

Interpersonal Functioning & Social Connectedness

Research on psychedelics highlights their potential to enhance interpersonal functioning and social connectedness, particularly through compounds such as psilocybin and MDMA. These compounds may facilitate therapeutic outcomes in various mental health disorders by fostering emotional connectivity and empathy among individuals.

What is Interpersonal Functioning & Social Connectedness?

Interpersonal functioning involves the ability of individuals to form and maintain relationships with others. It is crucial for mental health and well-being.

Social connectedness refers to the sense of belonging and connection with others. Low social connectedness is associated with a range of psychological issues and can lead to heightened feelings of isolation.

Pathophysiologically, deficits in interpersonal functioning may stem from underlying mental health conditions such as depression, anxiety, and trauma, which impair social cognition and emotional responses.

Symptoms of poor interpersonal functioning include difficulty in forming relationships, social anxiety, increased conflict in relationships, and a lack of empathy or emotional understanding of others.

Current Treatments

Standard treatments for issues relating to interpersonal functioning include psychotherapy, antidepressants, social skills training, and integrative therapies that focus on enhancing emotional and vocational support.

Psychedelic Effect Matrix

Systematic comparison of compound efficacy and evidence levels for Interpersonal Functioning & Social Connectedness.

Compound	Magnitude	Evidence	Consistency
Psilocybin Clinical trials consistently show that psilocybin enhances feelings of social connectedness and emotional empathy.	Large	High	Consistent
MDMA MDMA’s ability to reduce anxiety and foster trust is well-documented in therapeutic settings, improving interpersonal dynamics.	Large	High	Consistent
LSD While LSD shows promise, its effects on social connectedness are more variable compared to psilocybin and MDMA.	Medium	Moderate	Inconsistent
Ketamine Ketamine has been found to improve depressive symptoms, which can indirectly enhance interpersonal connections.	Medium	Moderate	Inconsistent

Psilocybin and Interpersonal Functioning & Social Connectedness

Psilocybin, the active compound in several species of mushrooms, has shown robust effects on enhancing interpersonal functioning. Clinical studies suggest that psilocybin can significantly elevate feelings of empathy and connectedness, particularly in group therapy settings. Participants in clinical trials noted improved relationships and social engagement post-administration, reflecting psilocybin's potential to create lasting benefits in social contexts.

View full Psilocybin profile →

MDMA and Interpersonal Functioning & Social Connectedness

MDMA, often associated with social bonding and increased emotional openness, has been included in numerous psychotherapy protocols to treat conditions like PTSD. Research indicates that MDMA promotes feelings of empathy, trust, and emotional safety, which can be particularly beneficial for individuals struggling with social anxiety or interpersonal conflicts. Its effects can lead to improved relational dynamics and better therapeutic outcomes due to enhanced communication skills.

View full MDMA profile →

Key Insights

1
Psychedelics like psilocybin and MDMA have been shown to improve interpersonal functioning by enhancing empathy and emotional awareness.
2
Recent clinical trials indicate that one-time treatments with psilocybin can lead to sustained increases in social connectedness and prosocial behaviour.
3
MDMA has demonstrated the ability to reduce fear responses and promote trust in therapeutic settings, enhancing interpersonal interactions among patients.
4
Psychedelic-assisted therapies show promise in treating social anxiety and conditions characterised by poor social functioning, such as PTSD and major depressive disorder.
5
The neurobiological mechanisms of psychedelics involve increased functional connectivity within brain networks related to social processing and emotion regulation.

Industrial Landscape

Key players in this space include the Multidisciplinary Association for Psychedelic Studies (MAPS), the Beckley Foundation, and various academic institutions conducting clinical trials focused on psychedelic research.

Quick Indicators

PrevalenceApproximately 300 million individuals worldwide experience issues with social connectedness and interpersonal relations.

Research Footprint

0Trials

0Papers

\"Ongoing clinical evaluations are investigating Interpersonal Functioning & Social Connectedness as a primary indication for various psychedelic compounds.\"

Key Organizations

4 Connected

Delix Therapeutics

Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.

MAPS

The description of the stakeholder

Lykos Therapeutics

Longer description of Lykos .. lorem ipsum ..

Leiden University

Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.